Midi Health vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 53)
Midi Health logo

Midi Health

ChallengerDigital Health

Women's Health

Raised $100M Series D (Feb 2026) at $1B unicorn valuation. 230K+ patients in 50 states. Digital health's first menopause-focused unicorn. Expanding to longevity and cardiology.

AI VisibilityBeta
Overall Score
C53
Category Rank
#258 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
51
Perplexity
48
Gemini
50

About

Midi Health became digital health's first menopause-focused unicorn in February 2026, raising $100 million in Series D financing at a $1 billion valuation. The company serves 230,000+ patients across all 50 states with clinician-led care for menopause, perimenopause, and midlife women's health — a market that has been systematically underserved by mainstream healthcare despite affecting 50 million American women.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

53
Overall Score
86
#258
Category Rank
#8
77
AI Consensus
79
stable
Trend
stable
51
ChatGPT
88
48
Perplexity
92
50
Gemini
83
55
Claude
90
57
Grok
89

Key Details

Category
Women's Health
Telehealth Pharmacy
Tier
Challenger
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Midi Health
Women's Health
Only Hims & Hers
Telehealth Pharmacy

Integrations

Only Midi Health

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.